EPO

China Medical System: New Drug Application of Desidustat Tablets Accepted in China

Retrieved on: 
Dienstag, April 23, 2024
CMS, Tablet, Desidustat, NMPA, NDA, National Medical Products Administration, Kidney failure, New Drug Application, Erythropoiesis, Anemia, Chronic kidney disease, CKD, Week, Patient, Dialysis, Prevalence, Marketing, Diagnosis, Advertising, EPO, Medical device

Desidustat Tablets are novel, oral HIF-PHI for treating anaemia in non-dialysis adult chronic kidney disease patients.

Key Points: 
  • Desidustat Tablets are novel, oral HIF-PHI for treating anaemia in non-dialysis adult chronic kidney disease patients.
  • The primary endpoint has indicated that Desidustat is more effective than placebo in increasing Hb level.
  • China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 22 April 2024, the New Drug Application (NDA) of Desidustat Tablets  (“Desidustat Tablets” or the “Product”) has been accepted by the National Medical Products Administration of China (NMPA).
  • Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

ORYZON Secures Another Important Patent for its Lead CNS Asset, Vafidemstat

Retrieved on: 
Montag, April 22, 2024
European Patent Convention, Communication, Schizophrenia, Aggression, Patent, DSM-IV codes, Borderline personality disorder, Genomics, Behavior, EPO, Pharmaceutical industry

The allowed claims cover the use of vafidemstat for the treatment of aggression and social withdrawal.

Key Points: 
  • The allowed claims cover the use of vafidemstat for the treatment of aggression and social withdrawal.
  • The patent, once granted, will not expire until at least 2038, excluding any potential patent term extensions that may provide additional protection.
  • Corresponding patent applications are pending in several additional major pharmaceutical markets, and a patent has already been granted in Russia.
  • “Upon issuance, this patent will significantly enhance Oryzon’s patent portfolio for vafidemstat, extending its commercial life in indications with large commercial potential”, stated Dr. Carlos Buesa, Chief Executive Officer of Oryzon.

ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio

Retrieved on: 
Freitag, April 19, 2024
Adenosine, IP, General counsel, European Patent Convention, RNA, AON, Oligonucleotide, Deamination, Science, Patent, Ribose, Therapy, ProQR, ADAR, EPO, Vaccine

This patent is part of ProQR’s intellectual property estate surrounding its Axiomer RNA editing platform and the current generation of its molecules.

Key Points: 
  • This patent is part of ProQR’s intellectual property estate surrounding its Axiomer RNA editing platform and the current generation of its molecules.
  • Since then, ProQR has filed multiple additional patent applications on further improvements to form a leading patent estate that supports ProQR’s ADAR-mediated RNA editing platform Axiomer.
  • Today ProQR has extensive patent protection related to the Axiomer RNA editing platform, including 15 published patent families, that currently comprise a total of 28 patents.
  • Beyond this, ProQR has several unpublished patent applications and continuously invests in expanding its IP estate around ADAR-mediated RNA editing.

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Freitag, April 12, 2024
UCLA, Congress, Sale, European Patent Office, Rutgers University, Chronic obstructive pulmonary disease, Outline of health sciences, Alopecia areata, Eosinophilic bronchitis, Safety, Skin, Drug development, European Patent Convention, Research, EASI, MD, Trial of the century, COPD, KOL, ADS, DHODH, Patent, Data, Patient, Liver, Dupilumab, Translational medicine, International Examiner, Harvard Medical School, ASLN, TREK, AA, Associate, Clinical trial, Emergency medicine, EPO, SAN, Contract research organization, Pharmaceutical industry

Cash used in operations for the fourth quarter of 2023 was $7.6 million compared to $12.0 million in the same period in 2022.

Key Points: 
  • Cash used in operations for the fourth quarter of 2023 was $7.6 million compared to $12.0 million in the same period in 2022.
  • Research and development expenses were $9.6 million in the fourth quarter of 2023 compared to $10.7 million in the fourth quarter of 2022.
  • General and administrative expenses were $3.2 million in the fourth quarter of 2023 compared to $2.7 million in the fourth quarter of 2022.
  • Net loss attributable to stockholders for the fourth quarter of 2023 was $13.5 million compared to a net loss of $14.5 million for the fourth quarter of 2022.

Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Dienstag, April 30, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Education, PFS, Abbreviated New Drug Application, European Patent Office, Experiment, Breast, NET, ASCO, RCC, Associate, Translation, European Medicines Agency, Hearing, PIN, Drug development, European Patent Convention, Metastasis, Conference, Liver disease, ADC, Stada Arzneimittel, Tablet, Baylor College of Medicine, Distinguishing, Therapy, NHT, Calendar, BIRC, Huntsman Cancer Institute, OS, Dean (education), Docetaxel, PKMYT1, Checkmate, Prostate cancer, ITT, EPO, USP1, University, PARP, Immunotherapy, Superior, PLK4, Patent, Royalty payment, Patient, Society, Acquisition, Translational research, Neoplasm, Share repurchase, Annual general meeting, Baylor University

Exelixis’ 2024 net product revenues guidance range includes the impact of a U.S. wholesale acquisition cost increase of 2.2% for both CABOMETYX and COMETRIQ effective on January 1, 2024.

Key Points: 
  • Exelixis’ 2024 net product revenues guidance range includes the impact of a U.S. wholesale acquisition cost increase of 2.2% for both CABOMETYX and COMETRIQ effective on January 1, 2024.
  • Based upon cabozantinib-related net product revenues generated by Exelixis’ collaboration partners during the quarter ended March 31, 2024, Exelixis earned $39.6 million in royalty revenues.
  • In January, Exelixis announced the appointments of Mary C. Beckerle, Ph.D., and S. Gail Eckhardt, M.D., to the Exelixis Board of Directors, effective January 5, 2024.
  • Exelixis management will discuss the company’s financial results for the first quarter of 2024 and provide a general business update during a conference call beginning at 5:00 p.m.

Poxel Provides a Financial Update for the First Quarter 2024 and Announces the Postponement of its 2023 Full-Year Results Release

Retrieved on: 
Montag, April 29, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Diabetes, Clinical Trials, Other Health, USD, Patient, Adenosine, DSM-IV codes, ADPKD, Sumitomo Pharma, Safety, Pharmacokinetics, European Patent Convention, JPY, Merck Serono, Kidney, Male, Adrenoleukodystrophy, VLCFA, EUR, Plasma, Serono, Disease, NASH, Fatty liver disease, Patent, ALD, AMN, POC, Biomarker, Merck, EPO, Pharmaceutical industry

As a result, TWYMEEG gross sales should exceed its FY 2023 guidance of JPY 4.2 billion (EUR 25.7 million)3 driven by a favourable sales trend in Japan.

Key Points: 
  • As a result, TWYMEEG gross sales should exceed its FY 2023 guidance of JPY 4.2 billion (EUR 25.7 million)3 driven by a favourable sales trend in Japan.
  • Beyond 2024, Poxel expects to receive escalating double-digit royalties as well as additional sales-based payments upon achievement of contractually based sales thresholds.
  • For territories not covered by its agreement with Sumitomo Pharma, Poxel is in ongoing discussions with potential partners for Imeglimin.
  • Net financial debt (excluding IFRS16 impacts and derivative debts) was EUR 47.4 million as of March 31, 2024, as compared to EUR 45.6 million as of December 31, 2023.

RTX recognized for industry leading innovation in patented technology

Retrieved on: 
Donnerstag, April 25, 2024
RTX, AI, European Patent Convention, Innovation, Research, Artificial intelligence, University, Patent, Annual report, EPO, Organization, Aviation

ARLINGTON, Va., April 25, 2024 /PRNewswire/ -- RTX (NYSE: RTX) received recognition from three separate organizations for innovation in patented technology. The Harrity Patent Analytics Patent 300® List, The European Patent Office (EPO) Patent Index, and The Clarivate™ Top 100 Global Innovators all issued their 2024 rankings naming RTX in the top 15 in each list.

Key Points: 
  • ARLINGTON, Va., April 25, 2024 /PRNewswire/ -- RTX (NYSE: RTX) received recognition from three separate organizations for innovation in patented technology.
  • "Innovation is the fuel that powers advanced technology development," said RTX Chief Technology Officer Juan de Bedout.
  • The EPO Patent Index in an annual report detailing the top applicants for European patents as well as highlighting trends in technology development and fields of innovation.
  • RTX ranked 10th on the 2024 list, the top ranking for an American company and the highest ranked in the aerospace and defense industry.

Patent Index 2023: Japan ranks 3rd for inventions in Europe

Retrieved on: 
Freitag, April 12, 2024
Invention, European Patent Convention, Nippon Telegraph and Telephone, Semiconductor, Suzuki, Growth, Mitsubishi Electric, Patent, Nissan, EPO

MUNICH, April 12, 2024 /PRNewswire/ -- According to the Patent Index 2023 published today by the European Patent Office (EPO), Japan was the 3rd most active country filing European patent applications, after the United States and Germany.

Key Points: 
  • MUNICH, April 12, 2024 /PRNewswire/ -- According to the Patent Index 2023 published today by the European Patent Office (EPO), Japan was the 3rd most active country filing European patent applications, after the United States and Germany.
  • The number of European patent applications from Japan has remained stable over the past few years (2022: 21 594; 2021: 21 672).
  • In total the EPO received 199 275 patent applications in 2023 from around the world, an increase of 2.9%, and the highest number ever.
  • Despite Japanese companies filing fewer patent applications in transport, Japanese carmakers remained among the most active firms filing vehicle-related patent applications at the EPO in 2023.

China's innovation fuels rise in European patent applications in 2023

Retrieved on: 
Freitag, April 12, 2024
Investment, Republic, Invention, European Patent Convention, CATL, Communication, South Korea, Patent, Amperex Electronic, EPO, BYD, Biotechnology, ZTE, Huawei

MUNICH, April 12, 2024 /PRNewswire/ -- Patent applications originating from the People's Republic of China at the European Patent Office (EPO) grew by 8.8% last year over 2022, according to the EPO's Patent Index 2023 published today.

Key Points: 
  • MUNICH, April 12, 2024 /PRNewswire/ -- Patent applications originating from the People's Republic of China at the European Patent Office (EPO) grew by 8.8% last year over 2022, according to the EPO's Patent Index 2023 published today.
  • In total, the EPO received 199 275 patent applications in 2023 from around the world, up 2.9% compared to 2022 and the highest number ever.
  • The top three fields for patent applications from China were digital communication (9.7% more applications in 2023 compared to 2022), electrical machinery and energy (+27.5%) and computer technology (+0.3%).
  • China was among the top five countries of origin for European patent applications in 2023 together with the United States, Germany, Japan and the Republic of Korea.

EQS-News: Heidelberg Pharma announces financial figures and reports on successful business performance in 2023

Retrieved on: 
Mittwoch, April 10, 2024
Malignancy, Spanish mythology, State university system, Patient, Sale, Renal cell carcinoma, Clinical trial, Neoplasm, Therapy, Depreciation, HPHA, USD, Marketing, GLP, Health, Research, ATACS, EPO, Immune system, ADC, BLA, ATAC, Food, Biologics license application, Disease, Magenta, Multiple myeloma, AACR, GCC, Annual report, FDA, Diagnosis, EUR, Supervisory board, Accounting, PET, EDT, Spacecraft, Amanitin, European Patent Convention, Patent, Eli Lilly and Company, Binghamton University, Pharmaceutical industry

Minority interest in Emergence sold: In summer 2023, Heidelberg Pharma sold its minority interest in Emergence Therapeutics AG, Duisburg, Germany, (Emergence).

Key Points: 
  • Minority interest in Emergence sold: In summer 2023, Heidelberg Pharma sold its minority interest in Emergence Therapeutics AG, Duisburg, Germany, (Emergence).
  • As a result, Heidelberg Pharma lost sales revenue in the low single-digit millions for the 2023 financial year.
  • In April 2023, Heidelberg Pharma signed a termination agreement with Magenta under which all licensed ATAC rights and some Magenta patents were assumed by Heidelberg Pharma.
  • The Heidelberg Pharma Group includes two entities, Heidelberg Pharma AG and Heidelberg Pharma Research GmbH.